SBC Medical Group (NASDAQ:SBC – Get Free Report) had its price target upped by investment analysts at BTIG Research from $8.00 to $10.00 in a research report issued on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research‘s price objective points to a potential upside of 36.05% from the company’s previous close.
SBC has been the subject of several other research reports. Wall Street Zen downgraded SBC Medical Group from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Weiss Ratings raised SBC Medical Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, October 9th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.
Check Out Our Latest Analysis on SBC Medical Group
SBC Medical Group Stock Performance
Shares of NASDAQ:SBC opened at $7.35 on Friday. The company has a market cap of $755.93 million, a P/E ratio of 14.70, a P/E/G ratio of 3.30 and a beta of 0.52. The stock’s 50-day moving average is $5.13 and its 200-day moving average is $3.98. SBC Medical Group has a 52-week low of $2.78 and a 52-week high of $7.39. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.27 and a current ratio of 3.31.
SBC Medical Group (NASDAQ:SBC – Get Free Report) last posted its quarterly earnings data on Friday, November 13th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.03. SBC Medical Group had a return on equity of 19.14% and a net margin of 27.26%. The business had revenue of $58.58 million for the quarter, compared to analyst estimates of $48.90 million. Equities research analysts predict that SBC Medical Group will post 0.44 earnings per share for the current year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC bought a new stake in shares of SBC Medical Group in the third quarter valued at about $36,000. Bank of New York Mellon Corp acquired a new stake in SBC Medical Group during the first quarter worth about $43,000. Bank of America Corp DE bought a new position in SBC Medical Group during the second quarter valued at about $35,000. Williams & Novak LLC increased its stake in SBC Medical Group by 31.2% during the second quarter. Williams & Novak LLC now owns 18,686 shares of the company’s stock valued at $58,000 after acquiring an additional 4,449 shares during the period. Finally, Deutsche Bank AG bought a new position in SBC Medical Group during the second quarter valued at about $58,000. Institutional investors and hedge funds own 60.82% of the company’s stock.
About SBC Medical Group
SBC Medical Group Holdings provides management and support services to medical institutions, with a focus on clinics offering aesthetic medicine. Its services include support for clinic operations, marketing, staff training, procurement and customer service, allowing affiliated medical providers to focus on patient care. The group is associated with the Shonan Beauty Clinic brand and a broader network of clinics offering services such as cosmetic surgery and dermatology. Its business is centered primarily in Japan, where it supports the operations and growth of affiliated medical institutions.
Further Reading
- Five stocks we like better than SBC Medical Group
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for SBC Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SBC Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.
